A Reuters report on Friday revealed that FDA researchers have found additional molecular evidence tying blockbuster asthma ...

RFK Jr. as HHS head is perhaps President-elect Donald Trump’s most controversial Cabinet pick now that Matt Gaetz has ...

The pharma is seeking full approval for its anticoagulation reversal drug Andexxa, which the FDA granted accelerated approval ...

Pending the FDA’s decision, compounding pharmacies will remain free to make and market versions of the blockbuster ...

Novartis’ up to $1.1 billion acquisition of gene therapy specialist Kate Therapeutics fits with the pharma’s plan to expand ...

Makary is a pancreatic surgeon at Johns Hopkins who became known for battling medical mistakes and in recent years has been ...

Readouts from Novo Nordisk and Viking Therapeutics at AASLD 2024 strengthen the argument for GLP-1 therapies as an emerging ...

Lilly will provide the funding and expertise to advance Laekna’s LAE102, a first-in-class monoclonal antibody targeting the ...

While the full impact of the Supreme Court decision remains unknown, the new regulatory landscape could be a net positive for ...

Massachusetts’ increased investment in the life sciences industry includes boosting its life sciences tax incentive program ...

The agreement will give Kuro enough capital to support the development and launch of its menin inhibitor ziftomenib.

Lilly’s muvalaplin is the first oral drug to show positive Phase II findings for Lp(a) reduction, eliciting up to an 86% drop ...